About ESI
ESI formed in 1998 to capitalize on our patented electrofoming process for producing innovative endovascular medical devies. At the core of ESI's philosophy exists a commitment to improve less-invasive medical devices and procedures by overcoming the limitations of current endovascular treatments.
ESI continues to invent, develop, and deliver novel and workable endovascular solutions that meet critical medical needs and allow ESI to remain relevant in the rapidly evolving medical device market.
Through the continued refinement of existing products and procedures and the development of new technologies, ESI’s broad product portfolio focuses on transcatheter-based technologies that represent an addressable worldwide endovascular market opportunity.
Owned by Richard Hines and a small group of investors, ESI holds all rights to the intellectual properties related to electroforming, photolithography, and the devices invented and developed by ESI. Our current line of products includes the ESI O-cluder, pleated stent, patch stent, helical stent, and a porous-gold drug-delivery system for drug-eluting stents.
ESI continues to build on our core technologies while directing future investment towards the goal of developing and marketing innovative products that answer specific medical needs and create value for our shareholders. As we look to the future, ESI’s strategy entails leading both the O-cluder and pleated stent through non-clinical—-laboratory and animal—-testing and the FDA approval process in order to commercialize each respective technology.